Day One Biopharma, a South San Francisco-based drug startup focused on pediatric cancer, raised $60m in Series A funding.
Backers included Canaan Partners, Atlas Venture, and Access Biotechnology.
The company intends to use the funds to continue to expand development of its clinical-stage oncology treatment acquired through Takeda Pharmaceutical Company Limited.
Led by Dr. Samuel Blackman, co-founder, pediatric oncologist, and Chief Medical Officer, Day One Biopharmaceuticals develops new therapies that change the outcome for people of all ages living with cancer. The company’s first program is DAY101, an oral, once-a-week, type II pan-RAF inhibitor that is currently being evaluated in human clinical trials.
The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop emerging cancer treatments that can help both children and adults living with cancer. Day One was incubated at Canaan through a focused effort to identify, acquire, and develop promising new treatments that could address childhood cancers.